125 related articles for article (PubMed ID: 38636303)
1. Neil 1 deficiency facilitates chemoresistance through upregulation of RAD18 expression in ovarian cancer stem cells.
Shukla D; Mandal T; Srivastava AK
Biochem Biophys Res Commun; 2024 Jun; 712-713():149907. PubMed ID: 38636303
[TBL] [Abstract][Full Text] [Related]
2. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
3. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.
Srivastava AK; Han C; Zhao R; Cui T; Dai Y; Mao C; Zhao W; Zhang X; Yu J; Wang QE
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4411-6. PubMed ID: 25831546
[TBL] [Abstract][Full Text] [Related]
4. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
5. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
6. MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.
Kwon JE; Jang Y; Yun BS; Kang S; Kim YH; Kim BG; Cho NH
Cell Prolif; 2024 May; 57(5):e13582. PubMed ID: 38030594
[TBL] [Abstract][Full Text] [Related]
7. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
8. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells.
Hao L; Wang JM; Liu BQ; Yan J; Li C; Jiang JY; Zhao FY; Qiao HY; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118878. PubMed ID: 33011193
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract][Full Text] [Related]
10. S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53.
Yang T; Cheng J; You J; Yan B; Liu H; Li F
Oncol Rep; 2018 Sep; 40(3):1574-1582. PubMed ID: 29956807
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
12. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract][Full Text] [Related]
13. UBE2B promotes ovarian cancer growth via promoting RAD18 mediated ZMYM2 monoubiquitination and stabilization.
Zeng X; Zheng W; Sheng Y; Ma H
Bioengineered; 2022 Apr; 13(4):8000-8012. PubMed ID: 35313791
[TBL] [Abstract][Full Text] [Related]
14. Co-expressed functional module-related genes in ovarian cancer stem cells represent novel prognostic biomarkers in ovarian cancer.
Gov E
Syst Biol Reprod Med; 2020 Aug; 66(4):255-266. PubMed ID: 32441533
[TBL] [Abstract][Full Text] [Related]
15. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitylation-dependent regulation of NEIL1 by Mule and TRIM26 is required for the cellular DNA damage response.
Edmonds MJ; Carter RJ; Nickson CM; Williams SC; Parsons JL
Nucleic Acids Res; 2017 Jan; 45(2):726-738. PubMed ID: 27924031
[TBL] [Abstract][Full Text] [Related]
17. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.
Alvero AB; Chen R; Fu HH; Montagna M; Schwartz PE; Rutherford T; Silasi DA; Steffensen KD; Waldstrom M; Visintin I; Mor G
Cell Cycle; 2009 Jan; 8(1):158-66. PubMed ID: 19158483
[TBL] [Abstract][Full Text] [Related]
18. CD166 promotes the cancer stem-like properties of primary epithelial ovarian cancer cells.
Kim DK; Ham MH; Lee SY; Shin MJ; Kim YE; Song P; Suh DS; Kim JH
BMB Rep; 2020 Dec; 53(12):622-627. PubMed ID: 32843129
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
Li SS; Ma J; Wong AST
J Gynecol Oncol; 2018 Mar; 29(2):e32. PubMed ID: 29468856
[TBL] [Abstract][Full Text] [Related]
20. DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1.
Cui T; Srivastava AK; Han C; Wu D; Wani N; Liu L; Gao Z; Qu M; Zou N; Zhang X; Yi P; Yu J; Bell EH; Yang SM; Maloney DJ; Zheng Y; Wani AA; Wang QE
Cell Death Dis; 2018 May; 9(5):561. PubMed ID: 29752431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
